Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

News >

Lead Researcher Discusses Durvalumab/Olaparib Combo in Breast Cancer

Caroline Seymour
Published: Wednesday, Jan 30, 2019

Susan M. Domchek, MD

Susan M. Domchek, MD
The combination of olaparib (Lynparza) and durvalumab (Imfinzi) demonstrated encouraging activity in patients with HER2-negative metastatic breast cancer with germline BRCA mutations, prompting an expansion cohort within the open-label phase II MEDIOLA trial, explained lead study investigator Susan Domchek, MD.

Following a 4-week run in, in which patients received 300 mg of olaparib monotherapy twice daily, patients continued on olaparib at the prespecified dose and were given 1.5 g of intravenous durvalumab every 4 weeks.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication